Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Lymphoma, Large B-Cell, Diffuse 80Leukemia, Myeloid, Acute 74Multiple Myeloma 70Breast Neoplasms 69Lymphoma, Non-Hodgkin 62Lymphoma 61Leukemia, Lymphocytic, Chronic, B-Cell 53Burkitt Lymphoma 53Recurrence 51Lymphoma, Follicular 51Myelodysplastic Syndromes 50Lymphoma, B-Cell 47Leukemia 43Triple Negative Breast Neoplasms 40Lymphoma, Mantle-Cell 38Neoplasms 37Hodgkin Disease 34Melanoma 33Lymphoma, B-Cell, Marginal Zone 32Hematologic Neoplasms 31Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Neuroblastoma 28Ovarian Neoplasms 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasm Metastasis 22Leukemia, Biphenotypic, Acute 22Pancreatic Neoplasms 21Sarcoma 18Myeloproliferative Disorders 17

Interventions

fludarabine 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Attributes × Cyclophosphamide × 1 year × Clear all
NCT05826535 2026-05-28

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Lyell Immunopharma, Inc.

Phase 1/2 Recruiting
270 enrolled
Lymphoid

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡